Literature DB >> 22693983

Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital.

Daniel T Farkas1, Arieh Greenbaum, Vinay Singhal, John M Cosgrove.   

Abstract

OBJECTIVES: Screening can increase early detection and reduce rates of advanced-stage cancer. Uninsured patients have been shown to have lower rates of screening. Previous studies have shown that uninsured patients and patients with Medicaid present with more advanced stages of cancer. The aim of this study was to measure the effect of insurance status in the setting of a safety-net hospital.
METHODS: Patients in our tumor registry with a diagnosis of breast or colorectal cancer between 2001 and 2010 were included. On the basis of their insurance status, they were divided into the following groups: Medicaid, Medicare, Medicare age <65 years, commercial, uninsured, and unknown. Cancer stage was recorded for each patient, with stages III and IV considered advanced disease. The primary end point was the rate of advanced disease in each patient group.
RESULTS: A total of 910 patients were included in the study: 836 (91.9%) insured, 54 (5.9%) uninsured, and 20 (2.2%) unknown. Of the insured patients, 301 (36.0%) had Medicaid; 237 (30.7%) of 836 insured patients had advanced disease, compared with 27 (50.0%) of 54 uninsured patients (odds ratio, 1.63; P = .003). Of patients with Medicaid, 83 (27.6%) of 301 had advanced disease, which was not statistically different from patients with other insurance.
CONCLUSIONS: In a safety-net hospital, patients with Medicaid had rates of advanced-stage cancer similar to those in patients with other types of insurance. However, patients with no insurance had significantly higher rates of advanced disease. This has significant ramifications in view of the new healthcare law, which will convert many patients from being uninsured to having Medicaid.

Entities:  

Mesh:

Year:  2012        PMID: 22693983

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  American Society of Clinical Oncology policy statement on medicaid reform.

Authors:  Blase N Polite; Jennifer J Griggs; Beverly Moy; Christopher Lathan; Nefertiti C duPont; Gina Villani; Sandra L Wong; Michael T Halpern
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

2.  The Impact of Healthcare Privatization on Access to Surgical Care: Cholecystectomy as a Model.

Authors:  Ayman Al-Jazaeri; Firas Ghomraoui; Wejdan Al-Muhanna; Ahmed Saleem; Hazem Jokhadar; Tareq Aljurf
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

3.  The effect of insurance status on outcomes after laparoscopic cholecystectomy.

Authors:  Samantha J Neureuther; Kamal Nagpal; Arieh Greenbaum; John M Cosgrove; Daniel T Farkas
Journal:  Surg Endosc       Date:  2012-12-18       Impact factor: 4.584

4.  Testing health information technology tools to facilitate health insurance support: a protocol for an effectiveness-implementation hybrid randomized trial.

Authors:  Jennifer E DeVoe; Nathalie Huguet; Sonja Likumahuwa-Ackman; Heather Angier; Christine Nelson; Miguel Marino; Deborah Cohen; Aleksandra Sumic; Megan Hoopes; Rose L Harding; Marla Dearing; Rachel Gold
Journal:  Implement Sci       Date:  2015-08-25       Impact factor: 7.327

5.  Colorectal Cancer Risk Factors and Screening Among the Uninsured of Tampa Bay: A Free Clinic Study.

Authors:  Ethan Y Song; Justin Swanson; Artish Patel; Madeline MacDonald; Alexandra Aponte; Noura Ayoubi; Lucy Guerra; Eduardo Gonzalez; Rahul Mhaskar; Abu-Sayeef Mirza
Journal:  Prev Chronic Dis       Date:  2021-02-25       Impact factor: 2.830

6.  Effectiveness of an insurance enrollment support tool on insurance rates and cancer prevention in community health centers: a quasi-experimental study.

Authors:  Nathalie Huguet; Steele Valenzuela; Miguel Marino; Laura Moreno; Brigit Hatch; Andrea Baron; Deborah J Cohen; Jennifer E DeVoe
Journal:  BMC Health Serv Res       Date:  2021-10-30       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.